Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D9OMQ3
|
|||
Drug Name |
GEN3013
|
|||
Drug Type |
Antibody
|
|||
Indication | Diffuse large B-cell lymphoma [ICD-11: 2A81; ICD-10: C83.3; ICD-9: 200] | Phase 1/2 | [1] | |
Follicular lymphoma [ICD-11: 2A80; ICD-9: 202] | Phase 1/2 | [1] | ||
Mantle cell lymphoma [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 1/2 | [1] |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | . | [2] |
T-cell surface glycoprotein CD3 (CD3) | Target Info | . | [2] | |
KEGG Pathway | Hematopoietic cell lineage |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT03625037) GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma. U.S. National Institutes of Health. | |||
REF 2 | DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing. EBioMedicine. 2020 Feb;52:102625. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.